Ductal Carcinoma In Situ (DCIS): Symptoms, Diagnosis, Stages & Treatment

Ductal carcinoma in situ (DCIS) is a non-invasive breast condition in which abnormal cells are confined to the milk ducts and have not spread into surrounding breast tissue. It’s often called “Stage 0 breast cancer.” Most DCIS is found on a routine mammogram, before any lump can be felt. Treatment usually involves surgery — lumpectomy or mastectomy — sometimes followed by radiation or hormone therapy, though a small, low-risk subset of patients may now be offered active monitoring as an alternative under specialist supervision. DCIS has a very good prognosis, but individual treatment decisions depend on grade, size, hormone-receptor status, and personal risk factors.

If you or someone you love has just seen the words “ductal carcinoma in situ” on a mammogram or biopsy report, this guide walks through what it means, how it’s diagnosed and graded, the treatment options doctors typically discuss, and what to expect if you’re exploring treatment in India as an international patient.

What Is Ductal Carcinoma In Situ?

DCIS is a collection of abnormal cells growing inside the milk ducts of the breast. The word “in situ” means “in its original place” — the abnormal cells haven’t broken through the duct wall to invade the surrounding fatty and connective tissue of the breast.

Because the cells haven’t invaded beyond the duct, DCIS cannot spread to lymph nodes or other parts of the body in its current form. This is the key difference between DCIS and invasive breast cancer, and it’s why DCIS is generally classified as Stage 0 rather than Stage I–IV.

DCIS accounts for roughly 1 in 5 newly diagnosed breast cancers in countries with organized mammography screening — a number that has risen steadily since mammography became widespread, simply because screening now catches disease that used to go undetected until it became invasive.

DCIS is not “nothing to worry about,” and it is not the same as invasive cancer either. It sits in a specific middle category that requires an accurate diagnosis, a clear explanation from your care team, and a treatment decision suited to your particular case — not a generic one.

Is DCIS Cancer, or Is It “Stage 0 Breast Cancer”?

Clinically, DCIS is classified within the breast cancer staging system as Stage 0. Pathologically, the cells found in DCIS have cancer-like features under the microscope. What makes DCIS different from Stage I–IV disease is that these cells have not gained the ability to invade — so, left untreated, some (not all) DCIS lesions may eventually develop the ability to invade surrounding tissue and become true invasive breast cancer, while others may never progress at all.

This is the central clinical challenge with DCIS: doctors currently cannot reliably predict, for an individual patient, which DCIS will progress and which won’t. That uncertainty is why most guidelines still recommend treating DCIS rather than ignoring it — while research into who can safely avoid treatment is actively ongoing (see the Active Monitoring section below).

DCIS vs. Invasive Breast Cancer vs. LCIS

These three terms are frequently confused. Here’s how they differ:

LCIS (lobular carcinoma in situ) is a separate condition — it’s generally treated as a marker of increased future breast cancer risk in both breasts, rather than as a lesion that itself needs to be surgically removed the way DCIS typically does. Don’t assume the two are managed the same way if you’ve seen both terms in a pathology report.

Symptoms of DCIS

DCIS usually causes no symptoms at all. Most cases are found on a routine screening mammogram, before a lump is large enough to feel.

When DCIS does produce a physical finding, it may include:

• A lump or thickened area in the breast (less common)
• Nipple discharge, sometimes blood-tinged
• Changes in the skin or nipple in rare cases

On a mammogram, the most common sign of DCIS is a cluster of microcalcifications — tiny calcium deposits that show up as small white specks. Not all microcalcifications mean DCIS; most turn out to be benign. That’s exactly why a suspicious cluster prompts further imaging and, often, a biopsy rather than an immediate cancer diagnosis.

Because DCIS is frequently silent, routine screening mammography — not waiting for symptoms — is what actually catches it early.

Causes and Risk Factors

Nobody can point to a single cause of DCIS in an individual patient. Research has identified factors associated with higher risk, including:

• Increasing age
• Family history of breast cancer
• Inherited genetic mutations (BRCA1, BRCA2, and others)
• Personal history of certain benign breast conditions
• Reproductive and hormonal factors (age at first period, age at menopause, hormone therapy use)
• Prior chest radiation, particularly at a young age

A risk factor is not a cause. Many women with several risk factors never develop DCIS, and some women with none of these factors do. Risk factors help guide screening intensity and, in some cases, genetic counseling — they don’t explain why any one person was diagnosed.

How DCIS Is Diagnosed

DCIS is diagnosed through a combination of imaging (mammogram, sometimes ultrasound or MRI) and a tissue biopsy that a pathologist examines under a microscope. Imaging alone cannot confirm DCIS — only pathology can.

The typical pathway:

1. Screening mammogram flags an abnormal area, often microcalcifications.
2. Diagnostic mammogram takes more detailed, magnified images of the specific area.
3. Breast ultrasound may be used to characterize the finding further, particularly in dense breast tissue.
4. Breast MRI is used selectively — for example, to assess the extent of disease in certain cases, or in women at high genetic risk — not as a routine step for everyone.
5. Core needle biopsy, often image-guided (stereotactic biopsy for calcifications), removes small tissue samples for pathology review. This is the step that actually confirms or rules out DCIS.
6. Pathology examination determines grade, hormone receptor status, and extent — the information that shapes the treatment discussion.

Not every patient needs every test on this list. Your specialist tailors the workup to what the initial mammogram shows.

Understanding DCIS Grade

Pathology grade is one of the most important pieces of information in a DCIS report, because it influences how the disease is discussed and monitored.

• Low-grade DCIS: Cells look closer to normal breast cells; tends to grow slowly.
• Intermediate-grade DCIS: Features between low- and high-grade.
• High-grade DCIS: Cells look markedly abnormal; more often associated with comedo-type necrosis (dying cell debris within the duct) and is generally treated with more caution.

Pathologists also record the extent (size) of the DCIS and, often, hormone receptor status (see below). Grade alone does not determine prognosis — it’s one input among several that your surgeon and oncologist weigh together.

What Does ER-Positive DCIS Mean?

Many DCIS lesions test positive for estrogen receptors (ER), meaning the abnormal cells have receptors that respond to estrogen. This matters because ER-positive DCIS may benefit from hormone (endocrine) therapy after surgery — most commonly tamoxifen, or an aromatase inhibitor in postmenopausal women — to reduce the risk of recurrence or a new breast cancer developing.

ER-negative DCIS does not respond to hormone therapy in the same way, so this treatment is generally reserved for ER-positive disease.

DCIS Staging

DCIS is classified as Stage 0 — non-invasive disease confined to the duct system. It does not have the Stage I–IV subcategories used for invasive breast cancer, because staging beyond Stage 0 is based on invasion, tumor size, and lymph node involvement — none of which apply to DCIS by definition.

One important nuance: sometimes a biopsy shows DCIS, but when the tissue is fully examined after surgery, a small area of invasive cancer is also found nearby. This is called “upstaging,” and it happens in a meaningful minority of cases — reported rates vary across studies, generally in a range that your surgical team can discuss based on your specific imaging and biopsy findings. This possibility is one reason surgical removal remains the standard recommendation for most DCIS, even when biopsy shows only non-invasive disease.

Can DCIS Become Invasive Breast Cancer?

Some DCIS, left untreated, can develop the ability to invade surrounding tissue and become invasive breast cancer. Not all DCIS does this, and researchers currently cannot reliably predict, case by case, which lesions will progress.

This uncertainty is exactly why DCIS is treated rather than left alone in most cases today — and it’s also exactly what the active surveillance trials described below are trying to resolve, so that lower-risk patients can eventually be identified with more confidence.

DCIS Treatment Options

There is no single correct treatment for DCIS. The right approach depends on grade, size, hormone receptor status, your breast anatomy, your age, your personal preferences, and your access to follow-up care. A multidisciplinary team — surgeon, pathologist, radiologist, and oncologist — typically discusses these factors together before presenting you with options.

The main approaches currently used or being studied are:

1. Active Monitoring / Surveillance (Selected Patients, Evolving Evidence)

For decades, essentially all DCIS was treated with surgery. That is starting to change for a specific, carefully defined subset of patients.

The COMET trial, published in JAMA in 2025, randomized women with newly diagnosed low-risk DCIS to either standard guideline-concordant surgical care or active monitoring (regular imaging and clinical follow-up, with or without hormone therapy, and surgery only if the disease changed). At two years of follow-up, active monitoring was not associated with a higher rate of invasive cancer compared with standard care. Similar trials — LORIS (UK), LORD (Europe), and LORETTA (Japan) — are studying the same question with different designs, and longer follow-up from all of these trials is still awaited.

What this means in practice, as of 2026:

• Active monitoring is not a universally available or universally appropriate option — it applies to a narrow group of patients with low-grade, hormone receptor–favorable, low-risk DCIS.
• The evidence so far covers a relatively short follow-up period (2 years in COMET’s primary analysis). Long-term safety over 5–10 years is still being established.
• Patients who choose or are offered active monitoring commit to regular mammograms and close specialist follow-up — it is not “doing nothing.”
• Standard, guideline-recommended treatment for most DCIS today is still surgery. Active monitoring should only be pursued as part of a structured program with an experienced breast specialist, not as a decision to simply skip treatment.

If you’re considering this route, ask your specialist directly whether your specific pathology and imaging findings would make you a reasonable candidate, and what monitoring schedule they would recommend.

2. Breast-Conserving Surgery (Lumpectomy)

Lumpectomy removes the area of DCIS along with a margin of surrounding healthy tissue, leaving most of the breast intact.

• Commonly used when DCIS is limited to one area of the breast and a clear margin can reasonably be achieved.
• If the pathology margin isn’t clear after the first surgery, a second surgery (“re-excision”) is sometimes needed.
• Usually followed by radiation therapy (see below) to reduce local recurrence risk, though this isn’t universal — your team will explain whether radiation is being recommended in your case and why.
• Generally has a shorter recovery than mastectomy.

3. Mastectomy

Mastectomy removes the entire breast and may be recommended when:

• DCIS is extensive or found in more than one area of the breast (multicentric)
• Clear surgical margins can’t reasonably be achieved with breast-conserving surgery
• A patient, after full discussion, prefers mastectomy for personal reasons (including risk-reduction preference)

It generally offers excellent local disease control, but it is major surgery with a longer recovery than lumpectomy, and reconstruction — if desired — is a separate decision made alongside your surgical team.

4. Radiation Therapy

When lumpectomy is performed, radiation to the remaining breast tissue is frequently recommended to lower the chance of local recurrence. Whether radiation is advised in your specific case depends on the size and grade of the DCIS, margin status, and other factors your radiation oncologist will walk through. Radiation is not typically given after mastectomy for DCIS, and it plays no role if active monitoring — rather than surgery — is the chosen path.

5. Hormone (Endocrine) Therapy

For ER-positive DCIS, tamoxifen or an aromatase inhibitor may be recommended after surgery to lower the risk of recurrence or a new breast cancer developing, in either the treated breast or the opposite breast. Endocrine therapy is an addition to — not a replacement for — surgery in standard treatment pathways, and it comes with its own side-effect profile that your oncologist will discuss (including menopause-like symptoms, and less commonly, effects on the uterus or bone density depending on the specific drug).

Do You Need a Sentinel Lymph Node Biopsy for DCIS?

By definition, DCIS has not spread to lymph nodes, so a routine lymph node procedure is not required for most DCIS patients, particularly those undergoing lumpectomy.

Sentinel lymph node biopsy may still be considered when:

• Mastectomy is being performed (because if invasive cancer is later found in the removed tissue, lymph node sampling can’t easily be done afterward)
• Imaging or biopsy findings raise suspicion that invasive cancer may be present alongside the DCIS
• The area of DCIS is large enough that occult invasion is a reasonable possibility

Your surgeon will explain whether this applies to your specific case and why.

Breast Reconstruction

For patients undergoing mastectomy, reconstruction is a separate decision that can be discussed with a plastic/reconstructive surgeon alongside your breast surgeon. Broad categories include:

• Immediate reconstruction — started at the same time as the mastectomy
• Delayed reconstruction — performed at a later date, sometimes after radiation is complete
• Implant-based reconstruction
• Autologous (flap) reconstruction, using the patient’s own tissue

The right option depends on breast anatomy, whether radiation is planned, and personal preference — this is a conversation, not a default.

DCIS Recurrence

DCIS can recur locally after treatment — either as DCIS again or, less commonly, as invasive cancer. Factors associated with recurrence risk include grade, margin width after surgery, extent of disease, and whether radiation or endocrine therapy was used. Regular follow-up mammography after treatment is designed specifically to catch any recurrence early, when it remains highly treatable.

It’s worth being clear-eyed here: recurrence risk is not zero with any treatment approach, including mastectomy, though mastectomy generally has the lowest local recurrence rate of the surgical options. Your team can walk you through how your specific pathology affects your individual risk — a single universal number oversimplifies a genuinely individual calculation.

DCIS Prognosis and Survival

DCIS, as a whole, has an excellent breast cancer–specific prognosis compared with invasive disease — this is one of the most reassuring, medically accurate things that can be said about it. That said, “excellent” is not the same as “guaranteed,” and your individual outlook depends on grade, treatment received, and ongoing follow-up.

Be cautious of any source — including this one — that states a single confident survival percentage without context. Published figures vary by study population, follow-up length, and treatment received, and they describe groups of patients, not individuals. Your oncologist is the right person to discuss what the data means for your specific diagnosis.

Genetic Counseling and Testing

Genetic counseling may be recommended if you have:

• A DCIS or breast cancer diagnosis at a younger age
• A strong family history of breast or ovarian cancer
• A personal history of multiple cancers
• A known inherited mutation (such as BRCA1/BRCA2) in the family
• Ashkenazi Jewish ancestry combined with a family history, per some guidelines

The testing is not recommended for every DCIS patient — a genetic counselor can help determine whether your personal and family history meets current criteria.

DCIS Treatment: A Practical Overview

This table is general educational guidance, not individualized medical advice. Your treatment plan should be made with your own breast specialist based on your full pathology and imaging.

DCIS Treatment Cost in India

Because DCIS treatment plans vary so widely — surgery type, whether radiation or endocrine therapy is needed, hospital tier, and city — there is no single accurate “DCIS package price.” What can be said honestly is what the total cost typically depends on:

• Diagnostic mammography and ultrasound/MRI where used
• Image-guided biopsy and pathology (including hormone receptor testing)
• Type of surgery (lumpectomy vs. mastectomy) and hospital stay
• Sentinel lymph node biopsy, if performed
• Radiation therapy course, if recommended
• Endocrine therapy medication, if prescribed
• Reconstruction, if chosen
• Follow-up imaging

Published estimates for breast cancer treatment in India as a whole (which typically includes more extensive disease than DCIS, often with chemotherapy) commonly cite ranges from roughly ₹1,00,000 to ₹10,00,000+ (approximately $1,200–$12,000+), varying enormously by city, hospital, and treatment complexity. Because DCIS is non-invasive and frequently does not require chemotherapy, a DCIS-specific treatment plan — surgery with or without radiation and endocrine therapy — typically falls toward the lower-to-middle portion of that broader breast cancer cost range, though this should always be confirmed with an itemized quote for your specific pathology, not treated as a fixed number.

The only reliable way to get an accurate figure is a personalized estimate based on your pathology report, imaging, and the specific hospital and surgeon you’re considering. Shifam Health can request an itemized cost estimate on your behalf once your reports are shared with a partner hospital’s breast oncology team.

Why International Patients Consider India for Breast Cancer Care

India has become a significant destination for international cancer patients, largely due to a combination of specialist availability, modern imaging and radiation infrastructure, and treatment costs that are substantially lower than in the US, UK, or Gulf region for comparable care — though “lower cost” should never be the only factor in a cancer treatment decision.

When evaluating any country or hospital for DCIS care, the questions that actually matter are:

• Does the center have a dedicated breast pathologist who reviews grade and hormone receptor status in-house or through a reliable partner lab?
• Is there a genuine multidisciplinary breast team — surgeon, radiologist, pathologist, radiation oncologist, medical oncologist — who discuss cases together, not a single surgeon working in isolation?
• What imaging and radiation technology does the center actually have on-site?
• Does the hospital have an international patient department that can coordinate report review, cost estimates, and follow-up communication after you return home?

What a Good Breast Cancer Center Should Offer

Rather than a generic “best hospitals” list, use this as a checklist when comparing centers, in India or elsewhere:

• A fellowship-trained or specialized breast surgical oncologist
• In-house or closely partnered breast pathology, including hormone receptor and, where relevant, HER2 testing
• Dedicated breast imaging (digital mammography, breast ultrasound, and access to breast MRI)
• On-site radiation therapy or a clearly coordinated radiation partner
• A functioning multidisciplinary tumor board for breast cases
• Reconstructive/plastic surgery availability if mastectomy is being considered
• An international patient coordination team experienced with medical record review, visa letters, and remote follow-up

Verify accreditation (JCI/NABH) and each specialist’s actual credentials directly with the hospital before committing — never rely solely on a facilitator’s claim.

The International Patient Treatment Journey

1. Share your reports — mammogram, biopsy, and pathology report — for review by a breast specialist.
2. Specialist review — a breast surgeon and pathologist assess your case, sometimes requesting additional slides or imaging for confirmation.
3. Treatment recommendation and cost estimate — you receive a written summary of the recommended approach and an itemized estimate.
4. Hospital and travel planning — hospital confirmation, medical visa documentation, and travel arrangements.
5. Consultation and, where needed, further workup on arrival.
6. Treatment — surgery, and radiation/endocrine therapy as recommended.
7. Recovery and discharge planning.
8. Remote follow-up — pathology results, wound checks, and ongoing coordination once you’re back home.

No reputable center can guarantee treatment outcomes, and a responsible facilitator will never promise them.

How Shifam Health Supports International DCIS Patients

Shifam Health is a medical tourism facilitator — not a hospital, oncology clinic, or diagnostic center, and not a substitute for your treating physician. What we help coordinate:

• Sharing your mammogram, biopsy, and pathology reports with a partner hospital’s breast oncology team for review
• Requesting an itemized treatment and cost estimate based on your actual reports
• Hospital and specialist shortlisting based on your specific diagnosis
• Medical visa documentation support
• Airport pickup, accommodation guidance, and local coordination during treatment
• Interpreter support where needed
• Remote follow-up communication once you’re back home

We don’t diagnose DCIS, recommend a specific treatment, or guarantee outcomes — those decisions belong to you and your treating breast specialist. Our role is to remove the logistical burden so you can focus on the medical decision itself.

If you or a family member has a DCIS diagnosis and are exploring treatment options in India, share your reports with our team on WhatsApp or through a short inquiry form. There’s no obligation, and most patients hear back with an initial specialist review within 24–48 hours.

Frequently Asked Questions

Sources & Further Reading:

• Hwang ES, Hyslop T, Lynch T, et al. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA. 2025;333(11):972-980.
• Partridge AH, Hyslop T, Rosenberg SM, et al. Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ. JAMA Oncology. 2025.
• National Cancer Institute (NCI) — Breast Cancer patient and clinician information
• American Cancer Society — Ductal Carcinoma In Situ (DCIS)
• American Society of Breast Surgeons — DCIS consensus guidance

This article is for general educational purposes and does not constitute individualized medical advice. Treatment decisions for DCIS should always be made in consultation with your own breast surgeon, pathologist, and oncology team, based on your complete pathology and imaging.